{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:29:19Z","timestamp":1784068159529,"version":"3.55.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41582-022-00636-7","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T16:03:02Z","timestamp":1646236982000},"page":"253-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenging the psychiatry\u2013neurology divide: the case of autoimmune encephalitis"],"prefix":"10.1038","volume":"18","author":[{"given":"Belinda R.","family":"Lennox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"636_CR1","unstructured":"National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management, https:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133 (NICE, 2014)."},{"key":"636_CR2","doi-asserted-by":"crossref","unstructured":"Endres, D. et al. Clinical manifestations and immunomodulatory treatment experiences in psychiatric patients with suspected autoimmune encephalitis: a case series of 91 patients from Germany. Mol. Psychiatry (2022).","DOI":"10.1038\/s41380-021-01396-4"},{"key":"636_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391\u2013404 (2016).","journal-title":"Lancet Neurol."},{"key":"636_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","volume":"78","author":"M Nosadini","year":"2021","unstructured":"Nosadini, M. et al. Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol. 78, 1333\u20131344 (2021).","journal-title":"JAMA Neurol."},{"key":"636_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2215-0366(20)30432-6","volume":"8","author":"AE Cullen","year":"2021","unstructured":"Cullen, A. E. et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case-control studies. Lancet Psychiatry 8, 109\u2013120 (2021).","journal-title":"Lancet Psychiatry"},{"key":"636_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1192\/bjo.2018.8","volume":"4","author":"JG Scott","year":"2018","unstructured":"Scott, J. G. et al. The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. BJPsych Open 4, 69\u201374 (2018).","journal-title":"BJPsych Open"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00636-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T13:06:23Z","timestamp":1651669583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00636-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1038\/s41582-022-00636-7","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"2 March 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.R.L. is running a trial of immunotherapy in antibody-positive psychosis, SINAPPS2 (), and has received research funding for related research from Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}